Latest News and Press Releases

This accelerates development of our clinical pipeline and leverages Hexstone’s previous investments in companies that have built digital asset treasuries.

This accelerates development of our clinical pipeline and leverages Hexstone’s previous investments in companies that have built digital asset treasuries.

Propanc announced its fiscal year-end following the filing of its annual 10-K report with the Securities and Exchange Commission on September 29, 2025.

A certificate of grant for Propanc’s “proenzyme composition” patent was received from the US Patent & Trademark Office.

Purchase of Ethereum will enhance a multi-faceted corporate strategy of cryptocurrency exposure, pharmaceutical drug development and asset acquisition.

Propanc is entering a transformational stage as it prepares for the advancement of its lead asset, “PRP”, to enter a Phase 1B, First-In-Human (FIH) study

Propanc Biopharma closes an underwritten public offering of 1,000,000 shares of its common stock at a price of $4.00 per share

Propanc completes pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price of $4.00 per share